EP0306263A3 - Novel hmg-coa reductase inhibitors - Google Patents

Novel hmg-coa reductase inhibitors Download PDF

Info

Publication number
EP0306263A3
EP0306263A3 EP88308010A EP88308010A EP0306263A3 EP 0306263 A3 EP0306263 A3 EP 0306263A3 EP 88308010 A EP88308010 A EP 88308010A EP 88308010 A EP88308010 A EP 88308010A EP 0306263 A3 EP0306263 A3 EP 0306263A3
Authority
EP
European Patent Office
Prior art keywords
coa reductase
reductase inhibitors
novel hmg
hmg
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP88308010A
Other versions
EP0306263B1 (en
EP0306263A2 (en
Inventor
Ta Jyh Lee
Gerald E. Stokker
Robert L. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0306263A2 publication Critical patent/EP0306263A2/en
Publication of EP0306263A3 publication Critical patent/EP0306263A3/en
Application granted granted Critical
Publication of EP0306263B1 publication Critical patent/EP0306263B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP88308010A 1987-09-02 1988-08-30 Novel hmg-coa reductase inhibitors Expired - Lifetime EP0306263B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9235387A 1987-09-02 1987-09-02
US92353 1987-09-02

Publications (3)

Publication Number Publication Date
EP0306263A2 EP0306263A2 (en) 1989-03-08
EP0306263A3 true EP0306263A3 (en) 1989-08-23
EP0306263B1 EP0306263B1 (en) 1992-03-18

Family

ID=22232821

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88308010A Expired - Lifetime EP0306263B1 (en) 1987-09-02 1988-08-30 Novel hmg-coa reductase inhibitors

Country Status (5)

Country Link
EP (1) EP0306263B1 (en)
JP (1) JPH0196151A (en)
CA (1) CA1307263C (en)
DE (1) DE3869282D1 (en)
DK (1) DK486088A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001148A (en) * 1989-06-07 1991-03-19 E. R. Squibb & Sons, Inc. Mevinic acid derivatives
EP0415488B1 (en) * 1989-08-31 1994-04-20 Merck & Co. Inc. 7-Substituted HMG-COA reductase inhibitors
CN114558618B (en) * 2022-01-04 2023-10-31 山东理工大学 Preparation method of azide-alkyne cycloaddition multi-acid-based photocatalyst

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183132A2 (en) * 1984-11-19 1986-06-04 Merck Frosst Canada Inc. A process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
EP0251625A2 (en) * 1986-06-23 1988-01-07 Merck & Co. Inc. Novel HMG-CoA reductase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX7065E (en) * 1980-06-06 1987-04-10 Sankyo Co A MICROBIOLOGICAL PROCEDURE FOR PREPARING DERIVATIVES OF ML-236B
US4376863A (en) * 1981-08-21 1983-03-15 Merck & Co., Inc. Hypocholesterolemic fermentation products
JPS5835144A (en) * 1981-08-27 1983-03-01 Sankyo Co Ltd Mb-530b derivative and its preparation
JPS5889191A (en) * 1981-11-20 1983-05-27 Sankyo Co Ltd Preparation of 3-hydroxy-ml-236b derivative
JPS59122483A (en) * 1982-12-28 1984-07-14 Nippon Chemiphar Co Ltd Novel monacolin derivative, its preparation and remedy for hyperlipemia containing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0183132A2 (en) * 1984-11-19 1986-06-04 Merck Frosst Canada Inc. A process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
EP0251625A2 (en) * 1986-06-23 1988-01-07 Merck & Co. Inc. Novel HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
DK486088A (en) 1989-03-03
EP0306263B1 (en) 1992-03-18
DK486088D0 (en) 1988-09-01
EP0306263A2 (en) 1989-03-08
JPH0196151A (en) 1989-04-14
DE3869282D1 (en) 1992-04-23
CA1307263C (en) 1992-09-08

Similar Documents

Publication Publication Date Title
JPS6426535A (en) Novel hmg-coa reductase inhibitor
GB2205837B (en) Phosphorus-containing hmg-coa reductase inhibitors
EP0211416A3 (en) Novel hmg-coa reductase inhibitors
EP0251625A3 (en) Novel hmg-coa reductase inhibitors
AU632836B2 (en) Novel peptidase inhibitors
EP0403487A4 (en) Novel hmg-coa reductase inhibitors
AU1025588A (en) Novel peptidase inhibitors
AU2058992A (en) HMG-COA reductase inhibitors
GB2205838B (en) Phosphorus-containing hmg-coa reductase inhibitors
PH27278A (en) Spiro-isoquinoline-pyrrolidine tetrones useful as aldose reductase inhibitors
EP0462661A3 (en) Novel 17beta-hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones as testosterone reductase inhibitors
AU5758490A (en) Novel acetylcholinesterase inhibitors
ZA886468B (en) Novel hmg-coa reductase inhibitors
EP0323866A3 (en) Novel hmg-coa reductase inhibitors
JPS6463595A (en) Ribonucleotide reductase inhibitor
EP0415488A3 (en) 7-substituted hmg-coa reductase inhibitors
JPS6426556A (en) Manufacture of novel intermediate and hmg-coa reductase inhibitor
EP0306263A3 (en) Novel hmg-coa reductase inhibitors
EP0320052A3 (en) Intermediates and processes for 6-carboxy hmg-coa reductase inhibitors
ZA874487B (en) Novel hmg-coa reductase inhibitors
EP0468974A4 (en) Novel hmg-coa reductase inhibitors
IE871654L (en) Novel hmg-coa reductase inhibitors
GB9303051D0 (en) 17b-nmonosubstituted carbamoyl-11-oxo-4-aza-5-a-androst-en-3-one testosterone-5-alpha reductase inhibitors
IE882652L (en) NOVEL HMG-CoA REDUCTASE INHIBITORS
IE861739L (en) Hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

ITCL It: translation for ep claims filed

Representative=s name: SOCIETA' ITALIANA BREVETTI S.P.A.

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19900105

17Q First examination report despatched

Effective date: 19910204

RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB IT LI NL

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB IT LI NL

REF Corresponds to:

Ref document number: 3869282

Country of ref document: DE

Date of ref document: 19920423

ET Fr: translation filed
ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19930628

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19930630

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19930729

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19930825

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19930831

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19940830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940831

Ref country code: CH

Effective date: 19940831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19950301

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19940830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19950428

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19950503

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050830